SABS SAB Biotherapeutics (SABS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001833214
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
59
13F, latest reported quarter
SAB Biotherapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for SAB Biotherapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 7, 2022.
- The trade is 0.0% of the 5,232,304 shares held after it.
- 2 other insiders bought within 30 days.
- 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Sullivan Eddie Joe bought about $1.5K of SABS on Dec 7, 2023; 2 other insiders bought within 30 days and 59 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 5,000 shares held after it.
- 2 other insiders bought within 30 days.
- 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER King Michael bought about $4.5K of SABS on Nov 30, 2023; 2 other insiders bought within 30 days and 59 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.0% of the 219,001 shares held after it.
- 2 other insiders bought within 30 days.
- 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman Reich Samuel J bought about $9.8K of SABS on Nov 29, 2023, the largest insider purchase at the company since 2022; 2 other insiders bought within 30 days and 59 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.2% of the 4,993,090 shares held after it.
- 1 other insider bought within 30 days.
- 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HAMILTON CHRISTINE E bought about $7.3K of SABS on Sep 13, 2022; 1 other insider bought within 30 days and 59 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.3% of the 5,230,564 shares held after it.
- 1 other insider bought within 30 days.
- 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER Sullivan Eddie Joe bought about $10.4K of SABS on Sep 7, 2022, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 59 funds added in the latest 13F quarter.6 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
59 funds bought in last quarter
more than 51% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.9% of the float short (float per yahoo 2026-10-26) · 5.0 days to cover · settled 2026-09-30
below 51% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SABS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-4.5%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SABS: institutional holders (13F)
13F holdings, latest reported quarter
7,967,207 sh
$31.1M
7,299,909 sh
$28.5M
6,627,501 sh
$25.8M
6,405,553 sh
$25.0M
4,401,500 sh
$17.2M
Congress trades in SABS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SABS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SABS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$408.9K position · as of 2026-06-30
0.5%
iShares Micro-Cap ETF
$567.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$38.2K position · as of 2026-06-30
0.0%
Fidelity Small Cap Value Index Fund
$236.9K position · as of 2026-06-30
0.0%
iShares Russell 2000 Value ETF
$1.5M position · as of 2026-06-30
0.0%
Avantis U.S. Small Cap Equity ETF
$243.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
1 active
2
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 59 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SABS financials
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.3M
four quarters, 2024-01-01 to 2024-12-31
Revenue, TTM SABS
| FY Dec 2025 | $1.3M |
| FY Dec 2024 | $1.3M |
| FY Dec 2023 | $2.2M |
| FY Dec 2022 | $23.9M |
| FY Dec 2021 | $60.9M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $114.7K |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
-966.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SABS
| FY Dec 2025 | +1,004% |
| FY Dec 2024 | -2,579% |
| FY Dec 2023 | -1,885% |
| FY Dec 2022 | -78.4% |
| FY Dec 2021 | -28.2% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM SABS
| FY Dec 2025 | -$45.1M |
| FY Dec 2024 | -$34.6M |
| FY Dec 2023 | -$25.3M |
| FY Dec 2022 | -$25.6M |
| FY Dec 2021 | -$9.0M |
| Jun 2026 | -$11.4M |
| Mar 2026 | -$15.3M |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$9.6M |
| Sep 2024 | -$6.4M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2023-06-30 (36 months older than the period end); equity 2026-06-30
Debt to equity SABS
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.02x |
| FY Dec 2023 | 0.01x |
| FY Dec 2022 | 0.02x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.05x |
| Mar 2025 | 0.03x |
| Dec 2024 | 0.02x |
| Sep 2024 | 0.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-99.58x
TTM operating cash flow over long-term debt only, 2023-06-30 (36 months older than the period end)
Cash flow to debt SABS
| FY Dec 2025 | -82.67x |
| FY Dec 2024 | -63.31x |
| FY Dec 2023 | -46.38x |
| FY Dec 2022 | -43.31x |
| FY Dec 2021 | n/a |
| Jun 2026 | -99.58x |
| Mar 2026 | -94.62x |
| Dec 2025 | -82.67x |
| Sep 2025 | -69.29x |
| Jun 2025 | -56.82x |
| Mar 2025 | -57.86x |
| Dec 2024 | -63.31x |
| Sep 2024 | -70.54x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-11.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SABS
| FY Dec 2025 | +15.0% |
| FY Dec 2024 | -81.9% |
| FY Dec 2023 | -95.5% |
| FY Dec 2022 | -53.8% |
| FY Dec 2021 | -120.2% |
| Jun 2026 | -11.3% |
| Mar 2026 | -0.3% |
| Dec 2025 | +15.0% |
| Sep 2025 | +18.6% |
| Jun 2025 | -127.5% |
| Mar 2025 | -92.4% |
| Dec 2024 | -81.9% |
| Sep 2024 | -174.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-9.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SABS
| FY Dec 2025 | +12.2% |
| FY Dec 2024 | -53.2% |
| FY Dec 2023 | -62.6% |
| FY Dec 2022 | -28.4% |
| FY Dec 2021 | -17.2% |
| Jun 2026 | -9.5% |
| Mar 2026 | -0.3% |
| Dec 2025 | +12.2% |
| Sep 2025 | +15.8% |
| Jun 2025 | -80.5% |
| Mar 2025 | -62.6% |
| Dec 2024 | -53.2% |
| Sep 2024 | -111.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital SABS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-58.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SABS
| FY Dec 2025 | -49.4% |
| FY Dec 2024 | -78.5% |
| FY Dec 2023 | -69.8% |
| FY Dec 2022 | -63.8% |
| FY Dec 2021 | -15.6% |
| Jun 2026 | -58.4% |
| Mar 2026 | -43.6% |
| Dec 2025 | -49.4% |
| Sep 2025 | -39.7% |
| Jun 2025 | -113.4% |
| Mar 2025 | -92.4% |
| Dec 2024 | -78.5% |
| Sep 2024 | -161.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SABS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$246.1M
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term debt only, 2023-06-30 (36 months older than the period end), minus cash 2026-06-30
Enterprise value SABS
| FY Dec 2025 | $168.1M |
| FY Dec 2024 | $26.7M |
| FY Dec 2023 | $303.9M |
| FY Dec 2022 | $239.4M |
| FY Dec 2021 | $3.4B |
| Jun 2026 | $290.5M |
| Mar 2026 | $175.2M |
| Dec 2025 | $168.1M |
| Sep 2025 | -$8.0M |
| Jun 2025 | $13.2M |
| Mar 2025 | $7.5M |
| Dec 2024 | $26.7M |
| Sep 2024 | $16.3M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield SABS
| FY Dec 2025 | -25.3% |
| FY Dec 2024 | -98.9% |
| FY Dec 2023 | -7.0% |
| FY Dec 2022 | -10.1% |
| FY Dec 2021 | -0.3% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -25.3% |
| Sep 2025 | -181.0% |
| Jun 2025 | -190.8% |
| Mar 2025 | -250.7% |
| Dec 2024 | -98.9% |
| Sep 2024 | -154.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SABS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | $1.3M | $2.2M | $23.9M |
| Operating income | -$49.0M | -$42.9M | -$38.1M | -$28.9M |
| Net income | $13.3M | -$34.1M | -$42.2M | -$18.7M |
| EPS (diluted) | -0.79 | -3.68 | -7.64 | -4.31 |
| Operating cash flow | -$44.8M | -$34.3M | -$25.1M | -$23.5M |
| Cash | $10.5M | $8.9M | $56.6M | $15.0M |
| Long-term debt | n/a | n/a | n/a | $541.6K |
SEC XBRL, fiscal years, as known on 2026-10-28
SABS Stock Sonar score 5/7 axes
Find similar shapesCompareSABS ranks highest on profitability (64th percentile) and institutional and government (51st), and lowest on growth (1st), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
